Pharmacological treatment of pathologic aggression in children
Authors:
- 1 January 2008
- journal article
- review article
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 20 (2) , 151-157
Abstract
Children with psychiatric illness may display pathologic aggression (PA) that is destructive, severe, chronic, and unresponsive to psychosocial and psychopharmacological treatment of their underlying condition(s) and psychosocial interventions specifically targeting PA. For this subset of children with PA, pharmacotherapy may be an appropriate treatment option to optimize their functioning. This article reviews pharmacological treatment studies for PA in children and the safety and efficacy of risperidone, olanzapine, lithium, divalproex sodium, methylphenidate, and typical antipsychotics in this patient population. While safety needs to be emphasized when prescribing medication for these patients, serious health and safety risks are also raised when PA is not effectively treated. Future research is needed to evaluate whether the long-term risks associated with the pharmacological treatment of PA outweigh the potential benefits to the child.Keywords
This publication has 39 references indexed in Scilit:
- A26-Week Open-Label Study of Quetiapine in Children with Conduct DisorderJournal of Child and Adolescent Psychopharmacology, 2007
- Risperidone in the Management of Disruptive Behavior DisordersJournal of Child and Adolescent Psychopharmacology, 2006
- A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Maintenance Treatment in Children and Adolescents With Disruptive Behavior DisordersAmerican Journal of Psychiatry, 2006
- Long-term safety and efficacy of risperidone in children with disruptive behaviour disordersEuropean Child & Adolescent Psychiatry, 2006
- Validity of DSM-IV Conduct Disorder in 4½–5-Year-Old Children: A Longitudinal Epidemiological StudyAmerican Journal of Psychiatry, 2005
- Risperidone Effects in the Presence/Absence of Psychostimulant Medicine in Children with ADHD, Other Disruptive Behavior Disorders, and Subaverage IQJournal of Child and Adolescent Psychopharmacology, 2004
- Long-Term, Open-Label Study of Risperidone in Children With Severe Disruptive Behaviors and Below-Average IQAmerican Journal of Psychiatry, 2004
- Trends in Antipsychotic Use in a Texas Medicaid Population of Children and Adolescents: 1996 to 2000Journal of Child and Adolescent Psychopharmacology, 2002
- Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Disruptive Behaviors in Children With Subaverage IntelligenceAmerican Journal of Psychiatry, 2002
- Divalproex Treatment for Youth With Explosive Temper and Mood Lability: A Double-Blind, Placebo-Controlled Crossover DesignAmerican Journal of Psychiatry, 2000